

Table 2. The occurrence of HLA-I LOH across different cancer types.

Cancer types	HLA-I LOH	HLA-I stable LOH at 1 locus	LOH at 2 loci	LOH at 3 loci	
Pan-cancer cohort	676/1482 (45.6%)	806	171	212	293
Cervical squamous cell carcinoma	34/50 (68.0%)	16	7	10	17
Lung squamous cell carcinoma	156/251 (62.2%)	95	33	50	73
Non-SqCC NSCLC	166/311 (53.4%)	145	50	58	58
Colorectal cancer	69/152 (45.4%)	83	21	19	29
Breast cancer	53/122 (43.4%)	69	10	18	25
Endocervical adenocarcinoma	9/22 (40.9%)	13	2	1	6
Stomach and esophageal carcinoma	57/142 (40.1%)	85	13	15	29
Ovarian cancer	52/135 (38.5%)	83	15	17	20
Pancreatic adenocarcinoma	21/63 (33.3%)	42	8	9	4
Kidney cancer	25/76 (32.9%)	51	8	3	14
Endometrial cancer	10/40 (25.0%)	30	0	4	6
Liver hepatocellular carcinoma	19/77 (24.7%)	58	3	7	9
Prostate adenocarcinoma	5/41 (12.2%)	36	1	1	3